National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background and Aims: The multisociety consensus nomenclature has renamed NAFLD to steatotic liver disease (SLD) with various subclassifications. There is a paucity of data regarding how the new nomenclature modifies our understanding of disease prevalence and patient phenotypes. Approach and Results: Using the National Health and Nutrition Examination Survey from January 2017 to March 2020, we included all participants aged 18 years or above with complete vibration-controlled transient elastography measures. SLD and its subclassifications [metabolic dysfunction-associated SLD (MASLD), MASLD + increased alcohol intake (MetALD), alcohol-associated liver disease (ALD), etiology-specific/cryptogenic] were defined according to consensus nomenclature. National SLD prevalence and subclassifications were estimated, and among key subgroups [age, sex, race/ethnicity, advanced liver fibrosis (liver stiffness measurement [LSM] ≥11.7 kPa)]. Among 7367 participants, 2549 had SLD (mean age 51 y, 57.7% male, 63.2% non-Hispanic White). The estimated prevalence of SLD was 34.2% (95% CI 31.9%–36.5%): MASLD 31.3% (29.2%–33.4%), MetALD 2% (1.6%–2.9%), ALD 0.7% (0.5–0.9%), etiology-specific/cryptogenic 0.03% (0.01%–0.08%). In exploratory analyses, participants classified as non-SLD with (vs. without) advanced fibrosis had a higher mean number of metabolic risk factors [2.7 (2.3–3.1) vs. 2.0 (1.9–2.0)] and a higher proportion with average alcohol use ≥20 g/d (women)/≥30 g/d (men) [20.9% (6.2%–51.3%) vs. 7.2% (6.1%–8.4%)]. In another exploratory analysis, increasing quantities of alcohol use remaining below the threshold for MASLD + increased alcohol intake were associated with advanced liver fibrosis in men, but not women. There was 99% overlap in cases of NAFLD and MASLD. Conclusions: Our findings highlight the utility of the new consensus nomenclature to address deficiencies present with the old nomenclature, and identify areas that require research to further refine classifications of SLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature
Lazarus, J. V., Newsome, P. N., Francque, S. M., Kanwal, F., Terrault, N. A., & Rinella, M. E. (2024) · Hepatology · doi:10.1097/hep.0000000000000696 · Cited by 438
Self-citationAlcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease
VanWagner, L. B., Ning, H., Allen, N. B., Ajmera, V., Lewis, C. E., Carr, J. J., Lloyd-Jones, D. M., Terrault, N. A., & Siddique, J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.08.012 · Cited by 74
Cited by
Israelsen, M., Francque, S., Tsochatzis, E. A., & Krag, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01811-7 · Cited by 348
Targeting MASLD and MASH in the US Hispanic/Latino Population: A Review
Cumpian, N. A., Gutierrez, J. A., Wu, W., & Saab, S. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.4769 · Cited by 22
Weight loss in MASLD restores the balance of liver fatty acid sources
Lambert, J. E., Ramos-Roman, M. A., Valdez, M. J., Browning, J. D., Rogers, T., & Parks, E. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci174233 · Cited by 20
Metadata
- Authors
- Lee, B. P., Dodge, J. L., & Terrault, N. A.
- Venue
- Hepatology
- Published
- 2023-09-20
- Volume
- 79
- Issue
- 3
- Pages
- 666-673
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4386910063
- Cited by
- 203
- References
- 5
- FWCI
- 33.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. https://app.cochat.ai/papers/10.1097/hep.0000000000000604
- The paper
- Lee, B. P., Dodge, J. L., & Terrault, N. A. (2024). National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology. https://doi.org/10.1097/hep.0000000000000604
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.